GFAP elevation has also been observed in the preclinical phase of AD [24, 32], and a large-scale study from the UK Biobank recently demonstrated that higher plasma levels of NfL and GFAP were associated with increased risk of all-cause dementia, including AD, FTD, and vascular dementia [33]. This evidence concerns the gene NEFL and Alzheimer disease.